These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 24832836)

  • 1. Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison.
    Baji P; Péntek M; Czirják L; Szekanecz Z; Nagy G; Gulácsi L; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S53-64. PubMed ID: 24832836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.
    Baji P; Péntek M; Szántó S; Géher P; Gulácsi L; Balogh O; Brodszky V
    Eur J Health Econ; 2014 May; 15 Suppl 1(Suppl 1):S45-52. PubMed ID: 24832835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of biosimilar-infliximab and originator-infliximab in combination with methotrexate in patients with active rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Int J Rheum Dis; 2018 May; 21(5):922-929. PubMed ID: 29671942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of biosimilar rituximab and originator rituximab in combination with methotrexate in patients with active rheumatoid arthritis: A Bayesian network meta-analysis
.
    Bae SC; Lee YH
    Int J Clin Pharmacol Ther; 2019 Apr; 57(4):188-196. PubMed ID: 30574867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of tumor necrosis factor inhibitors and their biosimilars in patients with rheumatoid arthritis having an insufficient response to methotrexate : A network meta-analysis.
    Ho Lee Y; Gyu Song G
    Z Rheumatol; 2023 Apr; 82(3):248-255. PubMed ID: 34223982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indirect comparison of biological treatments in refractory rheumatoid arthritis.
    Gallego-Galisteo M; Villa-Rubio A; Alegre-del Rey E; Márquez-Fernández E; Ramos-Báez JJ
    J Clin Pharm Ther; 2012 Jun; 37(3):301-7. PubMed ID: 21831256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents.
    Migliore A; Bizzi E; Petrella L; Bruzzese V; Cassol M; Integlia D
    BioDrugs; 2016 Apr; 30(2):105-15. PubMed ID: 26905069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
    Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
    CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis.
    Launois R; Avouac B; Berenbaum F; Blin O; Bru I; Fautrel B; Joubert JM; Sibilia J; Combe B
    J Rheumatol; 2011 May; 38(5):835-45. PubMed ID: 21239748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis.
    Wiens A; Venson R; Correr CJ; Otuki MF; Pontarolo R
    Pharmacotherapy; 2010 Apr; 30(4):339-53. PubMed ID: 20334454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane systematic review and network meta-analysis.
    Hazlewood GS; Barnabe C; Tomlinson G; Marshall D; Devoe D; Bombardier C
    BMJ; 2016 Apr; 353():i1777. PubMed ID: 27102806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
    JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis.
    Genovese MC; Sanchez-Burson J; Oh M; Balazs E; Neal J; Everding A; Hala T; Wojciechowski R; Fanjiang G; Cohen S
    Arthritis Res Ther; 2020 Mar; 22(1):60. PubMed ID: 32216829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of biosimilar adalimumab and originator adalimumab in combination with methotrexate in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Bae SC; Lee YH
    Clin Rheumatol; 2018 May; 37(5):1199-1205. PubMed ID: 29392511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis.
    Caporali R; Allanore Y; Alten R; Combe B; Durez P; Iannone F; Nurmohamed MT; Lee SJ; Kwon TS; Choi JS; Park G; Yoo DH
    Expert Rev Clin Immunol; 2021 Jan; 17(1):85-99. PubMed ID: 33305638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a meta-analysis update of 44 trials.
    Michaud TL; Rho YH; Shamliyan T; Kuntz KM; Choi HK
    Am J Med; 2014 Dec; 127(12):1208-32. PubMed ID: 24950486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis.
    Alfonso-Cristancho R; Armstrong N; Arjunji R; Riemsma R; Worthy G; Ganguly R; Kleijnen J
    Clin Rheumatol; 2017 Jan; 36(1):25-34. PubMed ID: 27726046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.